Plain-English translation of NCT06558227 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a new medication called ZG005, combined with a drug called , works better than another combination treatment for people with advanced liver cancer. Researchers want to see which pairing is most effective and safest as a first-line treatment. Both groups will receive intravenous infusions every three weeks.
Advanced hepatocellular carcinoma is a serious form of liver cancer that needs better treatment options. This trial aims to find out whether this new treatment approach is more effective than current standard options.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of three groups and receive intravenous infusions of medication every three weeks. Group A receives one dose of the new medication, Group B receives a higher dose of the new medication, and Group C receives the standard comparison treatment — all combined with . You'll have regular visits for blood tests, imaging scans, and check-ins to monitor how you're responding and any side effects.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China
Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Enrollment target
~90 participants
Started
October 2024
Primary completion
September 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Bo Liu
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.